Retatrutide
Note: Retatrutide is investigational and not FDA-approved. It is not available as an approved medication.
What it is
Retatrutide is an investigational compound being studied as a triple receptor agonist (GIP, GLP-1, and glucagon). It is not FDA-approved and is not available as a finished, approved medication. It remains in clinical research.
What it's used for
Being studied in clinical trials for weight management and metabolic conditions. Because it is investigational, there is no approved indication, no approved dosing, and the long-term safety profile is still being established. Anything sold as retatrutide outside a clinical trial is unregulated, and quality and safety cannot be assured. Talk to a healthcare professional before considering any research compound.
Typical dosing schedule
Dosing schedules differ by person and are set by a prescriber. The pattern below is a commonly described escalation — it is informational only, not a recommendation.
| Dose | Typical timing | Notes |
|---|---|---|
| Not established | Investigational | No FDA-approved dosing exists; doses studied in trials are not a recommendation and are managed under clinical supervision. |
Common side effects
Commonly reported side effects include in trials, the most commonly reported effects have been gastrointestinal (nausea, diarrhea, vomiting, constipation); the full safety profile is not yet established. Many people find symptoms ease over time, but persistent or severe symptoms should always be discussed with your prescriber. See our side-effects guide for management tips members commonly share.
Rough cost
No approved retail price exists; it is not legally marketed as a finished medication.
Pricing varies widely. See our cost & insurance guide for savings programs, prior-authorization basics, and more.
Discuss it with the community
Read real member experiences and ask questions: